Mezigdomide,Bortezomib,Dexamethasone,Daratumumab,Carfilzomib,Elotuzumab,Isatuximab,CC-92480,Pomalidomide
BMS,Takeda,Janssen,Amgen,Sanofi
['nct03989414', 'mmsm', ' pone ', ' pom ', 'bortezomib', 'lymphoma', 'borte', 'celmod', 'carfilzomib', 'emergent ']
update on mezi: potent celmod with 40% orr in imid refractory patients and 50% orr in bcma exposed. neutropenia aes managed with gcsf and dose modifications #ash22 #mmsm 
MD PhD, Specialized in Multiple Myeloma. Memorial Sloan Kettering Cancer Center. Karolinska Institute. Tweets are my own.